Clinical trials recruiting in Yvoir, Belgium

Phase breakdown

Conditions recruiting in Yvoir, Belgium

Recruiting trials in Yvoir, Belgium

• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  NCT01804686 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
  NCT07363044 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
  NCT06686615 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
  NCT07063745 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
  NCT06132893 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07522073 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
  NCT05899608 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Effect of IMT in Patients After Acute Exacerbations of COPD
  NCT07213128 · Phase: Not applicable (e.g. observational or device study) · Ages: 35 Years and older · Sex: All (male and female)
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
  NCT06456593 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female)
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
  NCT05169593 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• The CATALINA Study
  NCT05008081 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• The DRAGON 2 Trial
  NCT05428735 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
  NCT07359599 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Yvoir, Belgium?

35 recruiting trials have at least one study site in Yvoir, Belgium.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.